Growth impairment in pediatric inflammatory bowel disease

Pediatric Inflammatory Bowel Disease

Volumn , Issue , 2008, Pages 103-117

  Walters, Thomas D ^a   Griffiths, Anne M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883211327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73481-1_10     Document Type: Chapter

References (86)

1. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn disease. Gut 1993; 34:939-43.
2. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996; 129:81-8.
3. Karlberg J, Jalil F, Lam B, Low L, Yeung CY. Linear growth retardation in relation to the three phases of growth. Eur J Clin Nutr 1994; 48 Suppl 1:S25-43; discussion S43-4.
4. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol 2004; 180:247-55.
5. Rogol AD, Roemmich JN, Clark PA. Growth at puberty. J Adolesc Health 2002; 31:192-200.
6. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51:170-9.
7. Centers for Disease Control and Prevention NCfHS. CDC growth charts: United States, http://www.cdc.gov/growthcharts/.30-5-2000.
8. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995; 73: 17-24.
9. Zeferino AM, Barros Filho AA, Bettiol H, Barbieri MA. [Monitoring growth]. J Pediatr (Rio J) 2003; 79 Suppl 1:S23-32.
10. Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl 1990; 366:98-104; discussion 105.
11. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn disease. Gastroenterology 1988; 95:1523-7.
12. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18:165-73.
13. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16:373-80.
14. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681-91.
15. Kundhal P, Critch J, Hack C, Griffiths A. Clinical course and growth of children with Crohn disease. Can J Gastroenterol 2002.
16. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88:995-1000.
17. Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004; 114:1281-6.
18. Sawczenko A, Ballinger AB, Croft NM, Sanderson IR, Savage MO. Adult height in patients with early onset of Crohn disease. Gut 2003; 52:454-5; author reply 455.
19. Alemzadeh N, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CB, van Hogezand RA. Adult height in patients with early onset of Crohn disease. Gut 2002; 51:26-9.
20. Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ 1994; 308:1259-63.
21. Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 2002; 58 Suppl 1:7-10.
22. Kelts DG, Grand RJ, Shen G, Watkins JB, Werlin SL, Boehme C. Nutritional basis of growth failure in children and adolescents with Crohn disease. Gastroenterology 1979; 76:720-7.
23. Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80: 10-5.
24. Ballinger A, El-Haj T, Perrett D, et al. The role of medial hypothalamic serotonin in the suppression of feeding in a rat model of colitis. Gastroenterology 2000; 118:544-53.
25. Filipsson S, Hulten L, Lindstedt G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn disease. Scand J Gastroenterol 1978; 13:529-36.
26. Griffiths AM, Drobnies A, Soldin SJ, Hamilton JR. Enteric protein loss measured by fecal alpha 1-antitrypsin clearance in the assessment of Crohn disease activity: a study of children and adolescents. J Pediatr Gastroenterol Nutr 1986; 5:907-11.
27. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203-8.
28. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99:643-50.
29. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46:694-700.
30. Martensson K, Chrysis D, Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004; 19:1805-12.
31. Varghese S, Wyzga N, Griffiths AM, Sylvester FA. Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 2002; 35:641-8.
32. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93:841-50.
33. Bergad PL, Schwarzenberg SJ, Humbert JT, et al. Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 2000; 279:C1906-17.
34. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol 2003; 284:G646-54.
35. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16:3-34.
36. Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986; 91:830-6.
37. Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab 1977; 44:622-8.
38. Denson LA, Menon RK, Shaufl A, Bajwa HS, Williams CR, Karpen SJ. TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J Clin Invest 2001; 107:1451-8.
39. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999; 274:35553-61.
40. Colson A, Le Cam A, Maiter D, Edery M, Thissen JP. Potentiation of growth hormone-induced liver suppressors of cytokine signaling messenger ribonucleic acid by cytokines. Endocrinology 2000; 141:3687-95.
41. Cohney SJ, Sanden D, Cacalano NA, et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999; 19: 4980-8.
42. Ram PA, Waxman DJ. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 2000; 275:39487-96.
43. Shumate ML, Yumet G, Ahmed TA, Cooney RN. Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes. Am J Physiol Gastrointest Liver Physiol 2005; 289:G227-39.
44. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the-174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA 2005; 102:13260-5.
45. De Benedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142:4818-26.
46. Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm Res 2001; 56 Suppl 1:13-8.
47. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003; 53:205-10.
48. Russell RK, Drummond HE, Nimmo EE, et al. Genotype-phenotype analysis in childhood-onset Crohn disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005; 11:955-64.
49. Tomer G, Ceballos C, Concepcion E, Benkov KJ. NOD2/CARD15 variants are associated with lower weight at diagnosis in children with Crohn disease. Am J Gastroenterol 2003; 98:2479-84.
50. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99:2393-404.
51. Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006; 55:1114-23.
52. Levine A, Shamir R, Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn disease. Am J Gastroenterol 2005; 100:1598-604.
53. Griffiths AM, Otley AR, Hyams J, et al. A review of activity indices and end points for clinical trials in children with Crohn disease. Inflamm Bowel Dis 2005; 11:185-96.
54. Griffiths AM, Nicholas D, Smith C, et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. J Pediatr Gastroenterol Nutr 1999; 28:S46-52.
55. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn disease. Gastroenterology 1989; 97:905-10.
56. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn disease. Gastroenterology 1988; 94:603-10.
57. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn disease. Gut 1996; 38:543-8.
58. Bannerjee K, Camacho-Hubner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004; 38:270-5.
59. Walker-Smith JA. Management of growth failure in Crohn disease. Arch Dis Child 1996; 75:351-4.
60. Gassull MA, Stange EF. Nutrition and diet in inflammatory bowel disease. In: Satsangi J, Sutherland LR, eds. Inflammatory Bowel Diseases. London, UK: Elsevier, 2003:461-74.
61. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn disease. Cochrane Database Syst Rev 2001:CD000542.
62. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn disease. Aliment Pharmacol Ther 2000; 14:281-9.
63. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn disease in children. J Pediatr Gastroenterol Nutr 2000; 31:8-15.
64. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn disease. Gastroenterology 1995; 108:1056-67.
65. Seidman E, Griffiths AM, Jones A. Semi-elemntal diet versus prednisone in the treatment of acute Crohn disease in children and adolescents. Gastroenterology 1993; 104:A778.
66. Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn disease. J Pediatr Gastroenterol Nutr 2000; 31:3-5.
67. Rigaud D, Cosnes J, Le Quintrec Y, Rene E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn disease: elemental versus polymeric diet. Gut 1991; 32:1492-7.
68. Seidman E, Jones A, Issenman R. Cyclical exclusive enteral nutrition versus alternate day prednisone in maintaining remission of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 1996; 23:A344.
69. Whittington PF, Barnes HV, Bayless TM. Medical management of Crohn disease in adolescence. Gastroenterology 1977; 72:1338-44.
70. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16:47-54.
71. Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn disease: a meta-analysis. Aliment Pharmacol Ther 2000; 14:1419-28.
72. Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001; 33:75-80.
73. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000; 119:895-902.
74. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006; 55:437-41.
75. Nicholls S, Vieira MC, Majrowski WH, Shand WS, Savage MO, Walker-Smith JA. Linear growth after colectomy for ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr 1995; 21:82-6.
76. Griffiths AM, Wesson DE, Shandling B, Corey M, Sherman PM. Factors influencing postoperative recurrence of Crohn disease in childhood. Gut 1991; 32:491-5.
77. Davies G, Evans CM, Shand WS, Walker-Smith JA. Surgery for Crohn disease in childhood: influence of site of disease and operative procedure on outcome. Br J Surg 1990; 77:891-4.
78. Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn disease: risk factors for postoperative recurrence. Am J Gastroenterol 2001; 96:2169-76.
79. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease inflammatory bowel diseases April 2007, Vol 13(4): 424-430.
80. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39:46-52.
81. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease. Dig Liver Dis 2004; 36:342-7.
82. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003; 36:632-6.
83. Griffiths AM, Hyams JS, Crandall W. Height of children with Active Crohn Disease Improves During Treatment with Infliximab. Gastroenterology 2006; 130 Suppl2:A59.
84. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002; 51:127-35.
85. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn disease. N Engl J Med 2000; 342:1633-7.
86. Han X, Sosnowska D, Bonkowski EL, Denson LA. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 2005; 129:185-203.